Contineum Therapeutics, Inc.
CTNM
$9.80
-$0.59-5.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | 0.00 | 0.00 |
| SG&A Expenses | 16.73M | 15.68M | 13.44M | 10.88M | 9.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.03M | 59.08M | 50.90M | 43.52M | 38.62M |
| Operating Income | -66.03M | -59.08M | -50.90M | -43.52M | -38.62M |
| Income Before Tax | -56.86M | -49.83M | -42.26M | -35.62M | -31.73M |
| Income Tax Expenses | -- | -- | -- | -161.00K | -279.00K |
| Earnings from Continuing Operations | -56.86 | -49.83 | -42.26 | -35.46 | -31.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.86M | -49.83M | -42.26M | -35.46M | -31.45M |
| EBIT | -66.03M | -59.08M | -50.90M | -43.52M | -38.62M |
| EBITDA | -65.74M | -58.80M | -50.64M | -43.30M | -38.42M |
| EPS Basic | -2.20 | -1.97 | -4.90 | -4.85 | -7.14 |
| Normalized Basic EPS | -1.38 | -1.23 | -3.06 | -4.83 | -6.29 |
| EPS Diluted | -2.20 | -1.97 | -4.90 | -4.85 | -7.14 |
| Normalized Diluted EPS | -1.38 | -1.23 | -3.06 | -4.83 | -6.29 |
| Average Basic Shares Outstanding | 103.31M | 100.77M | 77.27M | 53.80M | 30.39M |
| Average Diluted Shares Outstanding | 103.31M | 100.77M | 77.27M | 53.80M | 30.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |